Clinical Trial Update: Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care [Phase 4]

View source ↗

Summary

Phase 4 study of 18 mg Selincro (nalmefene) used as-needed for alcohol dependence in primary care has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Dependence

Drugs mentioned

• Selincro (nalmefene hydrochloride dihydrate)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Alcohol Dependence | Phase 4 | Status: TERMINATED